Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
ETTX - Entasis Therapeutics Holdings Inc
$2.64
0.11(4.35%)9:00:00 PM 1/15/2021
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing Sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, a novel orally administered molecule that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant Gram-negative infections. The company has collaboration agreements with Zai Lab (Shanghai) Co., Ltd. for developing SUL-DUR. Entasis Therapeutics Holdings Inc. was incorporated in 2018 and is based in Waltham, Massachusetts.
Stock Chart
No summary

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
Peers

Related Peers

Stock news

    01/7/2021ETTX
    Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference

    WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021. The Company’s presentation will be available on demand starting Monday, January 11th,...

    12/1/2020ETTX
    We Think Entasis Therapeutics Holdings (NASDAQ:ETTX) Needs To Drive Business Growth Carefully

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

    11/17/2020ETTX
    Entasis Therapeutics to Participate in A.G.P.’s Virtual Healthcare Symposium

    WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that members of management will participate in A.G.P.’s Virtual Healthcare Symposium on Thursday, November 19th, 2020. The event will consist of 1-on-1 virtual investor meetings. Investors attending the conference virtually who are interested in meeting with Compan...

    11/5/2020ETTX
    Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update

    WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its third quarter 2020 financial results and provided a business update. “We made considerable progress during the quarter despite the sustained headwinds of the COVID-19 pandemic, as we continued to advance our Phase 3 registration clinical trials addressing Acine...

    10/14/2020ETTX
    Entasis Therapeutics Highlights Multiple Data Presentations at Virtual ID Week

    WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the company will have multiple data presentations at the virtual ID Week, being held October 21-25, 2020. The details of the poster presentations include:“Sulbactam-durlobactam (ETX2514) Is Active Against Recent, Multidrug-Resistant Acinetobacter baumannii Clinical...

    10/8/2020ETTX
    New Strong Sell Stocks for October 8th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.

    09/10/2020ETTX
    Entasis Therapeutics to Participate in Upcoming Healthcare Investor Conferences

    WALTHAM, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 15th, the Cantor 2020 Virtual Global Healthcare Conference on September 17th, and ...

    08/28/2020ETTX
    Entasis Therapeutics Announces $25 Million Private Placement

    Proceeds to support the ongoing ATTACK Phase 3 registration clinical trialWALTHAM, Mass., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today it has entered into a definitive agreement to sell securities in a private placement with Innoviva, Inc. (Nasdaq: INVA), a company with a portfolio of royalties, and another health...